MedTrace Logo

Glofitamab Combined With CAR-T Therapy in R/R DLBCL

NCT07326371 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2026-01-08

No results posted yet for this study

Summary

This study is a single-center, open-label, prospective study aimed at evaluating the efficacy and safety of Glofitamab combined with CAR-T therapy in patients with high-risk relapsed/refractory large B-cell lymphoma.

Conditions

  • DLBCL - Diffuse Large B Cell Lymphoma

Interventions

DRUG

Glofitamab

Glofitamab IV infusion will be administered as per the schedule specified in the respective arm.

DRUG

Obinutuzumab

Obinutuzumab IV infusion will be administered as per the schedule specified in the respective arm.

DRUG

Axicabtagene Ciloleucel

Axicabtagene Ciloleucel IV infusion will be administered as per the schedule specified in the respective arm.

DRUG

Relmacabtagene autoleucel (relma-cel)

Relmacabtagene autoleucel IV infusion will be administered as per the schedule specified in the respective arm.

Sponsors & Collaborators

  • Ruijin Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-31
Primary Completion
2027-07-31
Completion
2029-03-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07326371 on ClinicalTrials.gov